Evolent Health (NYSE:EVH) Issues Earnings Results

Evolent Health (NYSE:EVH) announced its quarterly earnings results on Thursday. The technology company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05), FiscalAI reports. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The company had revenue of $479.53 million for the quarter, compared to analyst estimates of $473.74 million. During the same quarter last year, the business earned ($0.27) EPS. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. Evolent Health updated its Q4 2025 guidance to EPS.

Evolent Health Price Performance

Shares of NYSE:EVH traded down $1.04 during midday trading on Friday, reaching $4.97. 8,699,049 shares of the company’s stock were exchanged, compared to its average volume of 2,714,930. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. The company’s 50 day simple moving average is $8.16 and its two-hundred day simple moving average is $9.04. Evolent Health has a 12 month low of $4.92 and a 12 month high of $15.56. The firm has a market capitalization of $583.43 million, a PE ratio of -3.08 and a beta of 0.58.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EVH. Durable Capital Partners LP bought a new position in shares of Evolent Health during the 2nd quarter worth approximately $72,326,000. 8 Knots Management LLC acquired a new position in Evolent Health during the second quarter worth $32,802,000. Goldman Sachs Group Inc. lifted its holdings in shares of Evolent Health by 162.2% during the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after acquiring an additional 1,754,520 shares during the period. Holocene Advisors LP acquired a new stake in shares of Evolent Health in the 2nd quarter valued at $5,945,000. Finally, Hudson Bay Capital Management LP boosted its stake in shares of Evolent Health by 92.2% in the 2nd quarter. Hudson Bay Capital Management LP now owns 760,211 shares of the technology company’s stock valued at $8,560,000 after purchasing an additional 364,664 shares in the last quarter.

Analysts Set New Price Targets

EVH has been the topic of several recent analyst reports. Stephens reiterated an “equal weight” rating and issued a $9.00 target price on shares of Evolent Health in a report on Wednesday, September 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evolent Health in a research report on Tuesday, September 9th. Piper Sandler increased their price objective on Evolent Health from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. Truist Financial boosted their target price on shares of Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolent Health in a research report on Wednesday, October 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.54.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.